Biofreeze
ApprovedSmall molecule
Biofreeze is one of 109 small molecule programs targeting Low back pain. It is currently in Approved.
4
Indications
5
Total Trials
1
Active Trials
108
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
778 competitors in Osteoarthritis
#DrugCompanyPhaseTrials
1Biofreeze
SSport and Spine Rehab Clinical Research Foundation
Approved
Ilaris
NovartisPreclinical
Toradol
RochePreclinical
Voltaren
CCerimon Pharmaceuticals
Preclinical
Bayer Aspirin
BayerPreclinical
Cataflam
NovartisPreclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Protonix
WWyeth-Lederle Vaccines
Preclinical
Catapres
Boehringer IngelheimPreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Osteoarthritis2 trials
Low back pain1 trial
Biofreeze® vs. a Placebo on Chronic Low Back Pain Walking Gait Characteristics and Pain
Active, not recruiting·SSport and Spine Rehab Clinical Research Foundation·Phase 4·NCT03888820·20 enrolled
Neck pain1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Biofreeze. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details